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Sutnlmary 
We and others have previously reported that melanoma-specific, cytotoxic T lymphocytes (CTL) 
define  a  minimum  of six  class  I-presented  peptide  epitopes  common  to  most  HLA-A2 + 
melanomas.  Here we show that three of these peptide epitopes are coordinately recognized by 
a CTL clone obtained by limiting dilution from the peripheral blood of an HLA-A2 + melanoma 
patient.  Tandem mass spectrometry was used to characterize and sequence one of these three 
naturally processed melanoma peptides.  One of the potential forms of the deduced peptide sequence 
(XXTVXXGVX,  X  =  I or L) matches positions 32-40 of the recently identified melanoma 
gene MART-1/Melan-A. This peptide (p939; ILTVILGVL) binds to HLA-A2 with an intermediate- 
to-low affinity and is capable of sensitizing  the HLA-A2 §  T2 cell line to lysis by CTL lines 
and clones derived from five different melanoma patients. A relative high frequency of anti-p939- 
specific effector cells appear to be present in situ in HLA-A2 + melanoma patients,  since p939 
is also recognized by freshly isolated tumor infiltrating  lymphocytes, p939 represents  a good 
candidate for the development of peptide-based immunotherapies for the treatment of patients 
with  melanoma. 
D 
uring  the last several years,  a number of studies have 
been  conducted  on  the  autologous  CD8 §  T  cell- 
mediated response to human melanoma (1-17). The emerging 
picture indicates  that  melanomas  express multiple  T  cell- 
defined epitopes, some of which are unique to a given tumor, 
while others are shared by allogeneic, HLA-matched mela- 
nomas (2-4, 6-9, 11-17).  These epitopes appear to represent 
short 9-10 amino acid peptides derived from tumor-associated 
antigens  that  are  presented  by MHC  class  I  antigens  to 
CD8 + T cells (5-9,  17,  18). While many class I alleles have 
been reported  to represent restriction  elements  for tumor- 
reactive CD8 § T  cells (6, 7,  10), the HLA-A2.1 allele (ex- 
pressed by 45%  of melanoma patients)  appears to play an 
immunodominant role in presenting melanoma epitopes (11). 
At least six different CD8 + T  cell-defined epitopes appear 
to be expressed by multiple HLA-A2 + melanomas (12,  13, 
19).  The identification  and  sequencing of these individual 
epitopes should allow for the design and testing of peptide- 
based immunotherapies  for the treatment  of melanoma. 
Materials and Methods 
Cell Lines.  Two melanoma cell lines have been used throughout 
this study. Me1624 (HLA-A2, -A3; ~B7, -B14; -Cw7: obtained from 
the Surgery Research Branch of the National  Cancer  Institute, 
Bethesda, MD) and Me19742 (HLA-A2, -A24; -B13, -B18; -Cw6, 
-Cw7: obtained from the Istituto Nazionale Tumori, Milan, Italy) 
were cultured in RPMI 1640 media supplemented with 10% heat- 
inactivated fetal bovine serum, 100 IU/ml penicillin, and 100 #g/ml 
streptomycin (all reagents from Gibco BRL, Gaithersburg, MD). 
The CTL clone A83 (autologous to Me19742) recognizes a common 
melanoma antigen and is restricted by HLA-A2 (16). The tumor 
infiltrating  (TIL)  1235 line and TIL 501.A42 clone were kindly 
provided by Dr.  Y.  Kawakami (National  Institutes  of Health, 
Bethesda, MD) and have been previously reported to recognize p27- 
35 of the MART-1 antigen presented in the context of HLA-A2 
(17). TILs 5403 and 6970 were isolated from metastatic melanoma 
lesions of HLA-A2  + patients as previously described (20), cultured 
for 7 d in the presence of autologous tumor,  and used directly as 
effector cells in cytotoxicity experiments. All TIL lines and clones 
were cultured in AIM-V media (Gibco BILL) supplemented with 
10% heat-inactivated human AB serum (Gibco), and 300 IU/ml 
rhll~2  (Cetus  Corp.,  EmeryviUe, CA). 
Acid Elution of  MHC Class 1-presented Melanoma Peptides.  Acid 
elution of, and reverse-phase high performance liquid chromatog- 
raphy (HPLC) resolution of, melanoma peptides was performed 
as previously described (12). Individual HPLC fractions were lyophi- 
lized and reconstituted in 200 #1 of Hank's buffered saline (Gibco 
BRL) and stored at  -20oC for use in cytolytic assays. Alterna- 
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and reconstituted in 50/~1 of 50% acetonitrile/50% water and stored 
at  -70~  until used. 
Reconstitution of T Cell Epitopes.  In peptide-pulsing assays, 10 
/~1 of reconstituted  peptides was added to microwells containing 
104 SlCr-labeled T2 cells, 0.2 #g human B2-microglobulin (B2-m; 
Sigma Chemical Co., St. Louis, MO), and 0.2/~g MA2.1 (anti- 
HLA-A2.1; American Type Culture Collection,  lkockville, MD, 
reference 21) monoclonal  antibody in a total of 125/d.  Peptide 
loading was facilitated by the presence of the B2-m and MA2.1 re- 
agents (22-24), and was allowed to proceed for 2 h at room tem- 
perature. Effector T cells were then added at a 10:1 effector-to-target 
cell ratio (unless otherwise stated) and cytolytic assays performed 
as previously described (12). 
HLA-A2 Stabilization  Assay.  Various  concentrations of synthetic 
peptides (as noted in text) were incubated for 18 h at room temper- 
ature with 106 T2 cells (25), I/~g B2-m, and 2 #g MA2.1 mono- 
clonal antibody. Cells were then washed twice with buffered saline 
and  stained with  FITC-conjugated  F(ab')2 goat  anti-mouse  Ig 
(Organon Teknika, Durham, NC) for 30 rain at 4~  After two 
additional washes with buffered saline, cells were fixed with 4% 
formalin (Fisher Scientific Co., Pittsburgh,  PA) and flow cytom- 
etry performed on a FACScan  |  (Becton Dickinson, Mountain View, 
CA) as previously noted (22). Results are reported as percentage 
of increase (over control)  of MA2.1  mean fluorescence channel 
number reactivity. Controls represent T2 cells cultured with ~2-m 
and MA2.1, in the absence of synthetic  peptide. 
Mass Spectrometric  Analysis.  Mel 9742 HPLC fractions 47 and 
48 were pooled, lyophilized, then reconstituted  in 50/~1 of 50% 
acetonitrile, 50% double distilled H20, and stored at  -70~  A 
10 #1 aliquot of this material was introduced into an API III tandem 
mass spectrometer (PE-Sciex, Ontario, Canada) via the articulated 
ion-spray interface. The sprayer needle was held at 4,500 V with 
a coaxial sheath of nebulizing  gas (compressed air) flow. Profile 
mass spectrum was obtained for peptide samples by scanning the 
first quadrupole from mass-to-charge (m/z) 500 to 1,600 in 3.37 s. 
The final spectrum was averaged  from 10 scans. A mass spectra/mass 
spectra (MS/MS) product ion spectrum was obtained for the p941 
by scanning the fragment  ions resulting  from collision with Ar 
gas. The sequence  was assigned as XXGVXXTVX, where X  = iso- 
leucine or leucine, each with residue mass of 113. 
Synthetic  Pepticles.  Peptides  were synthesized  using FMOC chem- 
istry by the Peptide Synthesis Facility (Shared Resource) of the Pitts- 
burgh  Cancer  Institute.  Each  peptide  was  purified  to  >95% 
homogeneity by reverse-phase (RP) HPLC and the identity of each 
peptide confirmed by MS/MS. The following peptides were syn- 
thesized:  p939/MART-1  32-40:ILTVILGVL;  gpl00  280-288: 
YLEPGPVTA (9); HIV-nef 73-82:QVPLRPMTYK (26); influenza 
A matrix,  Flu M1 58-66:GILGFVFTL  (24); p53  186-196:DGL- 
APPQHLIR (22); and p53 264-272:LLGRNSFEV  (22). 
Results 
Specific Recognition of HLA-A2-presented Melanoma Peptides 
by CTL Clone A83.  Melanoma 9742 (Md 9742) and mda- 
noma 624 (Mel 624) were acid treated (12) and peptides ob- 
tained from "~5  x  109 cell equivalents. These peptides were 
then resolved by P,P-HPLC (see Materials and Methods for 
details).  Aliquots of individual  fractions were pulsed onto 
the HLA-A2 + T2 cell line,  in the presence of human/32-m 
and the anti-HLA-A2 monoclonal antibody MA2.1, and tested 
for recognition by antimdanoma CTL done A83 in 4-h cy- 
totoxicity assays. Three bioactive peaks were identified for 
autologous Mel 9742 peptides, resolving in HPLC fractions 
42-43, 45, and 47-48 (Fig. 1). A similar pattern of bioactive 
peaks was identified for allogeneic HLA-A2 + Mel 624 frac- 
tionated peptides (Fig.  1). Peak 1 (HPLC fraction 42-43) and 
peak 3 (HPLC fractions 47-48) exhibited comparable efficacy 
in sensitizing the T2 target cell to lysis by CTL clone A83, 
with peak 2 (HPLC fraction 45) displaying a somewhat lesser 
capacity to do so. HLA-A2 restricted, melanoma-specific  TIL 
1235 and CTL clone A42 also recognized these same A83- 
identified bioactive peaks as detected by cytolysis of T2 peptide- 
pulsed target cells, with peak 2 reactivity approximating that 
of peaks  1 and 3  (Fig.  1). 
Mass Spectrometric  Analysis.  Me19742 HPLC fractions 47 
and 48 (peak 3) were pooled and analyzed using tandem mass 
spectroscopy, 10/~1 of fractionated material,  corresponding 
to  20%  of the  pooled  fractions  and  representing  109 cell 
equivalents, were injected into the electrospray ionizing source 
and the MS of the peptides recorded on a triple quadrupole 
mass spectrometer (PE-Sciex). The summation of mass spectra 
for peptides with m/z  =  500-1,600 is reported in Fig. 2 A. 
At least 39 different peptides were detected, with one pep- 
tide  (m/z  =  941)  representing  the  predominant  species. 
CoUision-induced  dissociation  was performed  on  this  ion 
yielding the daughter ion spectrum shown in Fig. 2 B. The 
spectra was interpreted  as defining a nine-amino  acid pep- 
tide  of Mr  -  939  with  the  sequence XXXTVXXGVX, 
where X  =  isoleucine or leucine (single letter amino acid 
designations).  Since isoleucine and leucine exhibit identical 
masses (Mr  --  113), 32 potential variants of this peptide se- 
quence are possible. A search of the GenBank database yielded 
a complete homology for one of these sequences, ILTVILGVL, 
with a recently cloned melanoma-associated  gene Melan-A (ac- 
cession number HSU06654, 15) also known as MART-1 (14). 
p939 Binds to HLA-A2 with Intermediate-to-Low  A.~nity. The 
p939 sequence ILTVILGVL was synthesized and shown to 
elute in HPLC fractions 48/49, approximating the naturally 
processed bioactive form eluted from Mal 9742.  This pep- 
tide was then  analyzed for its ability to bind  to HLA-A2 
using an HLA-A2-specific stabilization assay implementing 
the T2 cell line (22, 27). The T2 cell line exhibits severely 
depressed cell surface class I expression resulting from a genetic 
lesion affecting peptide transport into the endoplasmic retic- 
ulum (25). T2 expression of class I (in particular HLA-A2) 
at the cell surface can be enhanced by incubation at reduced 
temperature in the presence of exogenous 3a-m and peptides 
capable of binding  to the HLA-A2 allele  (22-24).  We in- 
cubated a panel of synthetic peptides, induding p939, with 
the T2 cell line at room temperature  (23~  for 18 h  and 
evaluated their capacity to stabilize HLA-A2 expression on 
the cell surface of T2 cells. Those peptides binding to HLA- 
A2 yielded an elevated reactivity with the MA2.1 (anti-HLA- 
A2) monodonal antibody compared with non-peptide-treated 
or irrelevant peptide-treated T2 cells. By performing a pep- 
tide dose titration  analysis,  a qualitative  assessment of the 
relative binding capacity of each peptide for HLA-A2 was 
obtained (22).  Analysis of a series of peptides revealed  that 
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Figure  1.  Melanoma  TIL lines 
and clones recognize three predom- 
inant  epitopes  resolved  by  RP- 
HPI.C. MHC class I-presented pep- 
tides derived from Me19742 or Mel 
624 were extracted and fractionated 
by RP-HPLC. After lyophilizing, 
each fraction  was reconstituted  in 
200 #1 of buffered saline and 10/~1 
used to pulse onto SlCr-labeled T2 
target cells in the presence of human 
~2-m and the anti-HLA-A2 mono- 
clonal antibody MA2.1 (as described 
in Materials  and  Methods).  CTL 
were then added at an effector-to- 
target cell ratio of 2:1 (Clone A83) 
or 10:1 (TIL 1235 and Clone A42) 
in a standard 4-h cytotoxicity assay. 
HPLC fractions  1-38  pulsed onto 
the T2 cell line were not recognized 
by CTL. 
the Flu M1 58-66 and p53 274-282 peptides were quite effec- 
tive in stabilizing HLA-A2 expression  on the T2 cell line 
(half-maximal activity at '~5 riM), while the p939 peptide 
was less effective (half-maximal activity at '~200 nM) (Fig. 
3). The efficacy of the p939 peptide was comparable to that 
observed for the gpl00 280-288 peptide, recently identified 
by Cox et al. (9) as a melanoma-assodated, HLA-A2-presented 
T  cell epitope. The gpl00 280-288  peptide was similarly 
reported to bind HLA-A2 with intermediate-to-low affinity 
(9). As controls, the p53 186-196 stabilized  HLA-A2 very 
poorly and the HLA-A3 binding HIV-nef 73-82 peptide did 
not stabilize HLA-A2, as previously reported (22). 
Reconstitution of a T Cell Epitope by p939.  Epitope recon- 
stitution experiments using p939 were performed and sen- 
sitization of T2 cells to lysis by antimelanoma CTL was evalu- 
ated over a wide range of peptide concentrations (250 riM-2.5 
pM) (Fig. 4). Four different HLA-A2 restricted, antimela- 
noma CTL were evaluated in these studies: the bulk cultured 
TIL 1235 line, two CTL clones (A83 and A42), and the fresh 
TIL 6970 line. Despite the apparent low affinity of p939 for 
HLA-A2, each of these CTL recognized peptide-pulsed T2 
targets.  Interestingly, while half-maximal sensitization for 
lysis mediated by TIL 1235, clone A83, and TIL 6970 were 
reached at ",~10 pM of peptide, the A42 clone required ~3,000 
pM of peptide for half-maximal sensitization. TIL 1235 and 
CTL clone A42 recognition of p939-pulsed T2 targets also  .ooj 
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Figure  2.  Mass  spectrometric 
analysis of Me19742 fraction 47/48 
peptides. HPLC fractions 47 and 48 
derived  from 5  x  109 melanoma 
9742 cells were combined and 10 #1 
corresponding  to one-fifth  of the 
original  volume was injected into 
the dectrospray ionization source of 
a triple quadrupole mass spectrom- 
eter (PE-Sdex).  Summation of the 
mass  spectra  obtained  in  the 
500-1,600 m/z range is depicted in 
A. The (M+H) + ion at  m/z  = 
941 was selected for fragmentation 
to generate sequence data and used 
to generate a similar CID spectrum 
(shown in B). Predicted (and actual, 
underlined)  masses for  the  frag- 
ments of the type b (carboxyl ter- 
minal cleavage)  are shown above and 
type y  (amino  terminal  cleavage) 
below  the  deduced  sequence 
XXTVXXGVX  (Mr  =  939), 
where X  =  isoleucine or leucine. 
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Figure  3.  p939 binds to HLA-A2 with moderate-to-low affinity. The 
stabilization of HLA-A2 on the T2 cell line in the presence of exogenous 
peptide was evaluated as outlined in Materials and Methods using the in- 
dicated synthetic  peptides.  HLA-A2 expression was evaluated using  the 
MA2.1 (anti-HLA-A2 monoclonal antibody)  in indirect immunofluores- 
cence assays monitored by flow cytometry.  Data  are reported  as percent 
increase in MA2.1  reactivity relative to T2 incubated  in the absence of 
peptide. A, p53-1; El, Flu M1; O, gpl00; A, p939; I-1, p53-2; @, HIV-nef. 
resulted in peptide-spedfic release of interferon-3, at p939 doses 
as low as 1 pM (data not shown). An additional HLA-A2- 
restricted fresh melanoma TIL 5403 was also able to recog- 
nize and lyse T2 target cells pulsed with p939 peptide (data 
not shown). CTL recognition of T2 presented p939 could 
be inhibited by addition of the anti-HLA-A2 monoclonal an- 
tibody CRll-351  (data not shown). 
Discussion 
We  have  identified  a  naturally  processed,  melanoma- 
associated  epitope  recognized by  five  distinct  HLA-A2- 
restricted, tumor-specific CTL lines and clones. This peptide 
was isolated from melanoma cell surface HLA-A2 class I com- 
plexes by mild add elution. The sequence of this peptide (p939: 
MART-1/Melan-A 32-40; ILTVILGVL) was deduced by mass 
spectrometry and a GenBank database search for homology, 
representing the second successful use of this technology to 
identify a tumor-associated epitope (9). 
Interestingly, the p939 epitope represents one of three epi- 
topes coordinately recognized by two distinct antimelanoma 
CTL clones (A83 and A42) derived from two different HLA- 
A2 + patients (14, 16). The other two epitopes may be rep- 
resented by MART-l-derived nonameric peptides MART-1 
27-35;AAGIGILTV and MART-1 29-37;GIGILTVIL, since 
the CTL clone A42 and TIL 1235 used in this study have 
been recently reported to react with these sequences (17). These 
latter two sequences have not been proven to be naturally 
processed and presented by melanoma. If they represent nat- 
uraUy processed and HLA-A2-presented epitopes, this would 
support the recognition of three distinct and overlapping pep- 
tide sequences (all share the MART-1 32-35;ILTV sequence) 
derived from a single protein precursor (MART-l) by two 
independent CTL clones. 
The high avidity of clone A83 for p939 is somewhat sur- 
prising since clone A83 is an autoreactive CTL; cross-reacting 
with melanoma and with normal melanocytes  (16). If an- 
titumor reactivity represents autoreactivity in human mela- 
noma, the role of positive and negative selection in main- 
taining such clonotypic T cells in vivo is of significant interest. 
The "differential avidity" model (28) could account for the 
positive selection of clones such as A83. In this model, the 
critical parameter is the number of TCR engaged with pep- 
tide-MHC complexes on APC. When this number is mod- 
erate, positive selection may occur. The combination of a high 
affinity TCR with a specific peptide epitope displaying a low 
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Figure 4.  Epitope reconstitution 
with p939. Melanoma-specific  CTL 
(cultured  TIL  1235, clone  A83, 
clone  A42,  and  fresh  TIL 6970) 
were  assayed in  4-h  cytotoxicity 
assays at effector-to-target  ratios of 
10:1 against  stCr-labeled  T2 cells 
pulsed with p939 at the indicated 
concentrations. Lysis  of T2 cells not 
pulsed with p939 was <5%. 
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commodate such moderate TCR engagement. Such a model 
makes it harder  to justify positive selection of clones such 
as A42, displaying very low avidity for p939, unless we as- 
sume that clone A42 could have been positively selected by 
a different peptide (such as MART-1 27-35; AAGIGILTV 
or MART-1; GIGILTVLI) for which it may have a far higher 
avidity. We are currently evaluating this possibility by com- 
parative epitope titrational analyses using the T2 presenting 
cell line. 
Of some  concern,  Kawakami  et  al.  (17)  have  recently 
screened a series of overlapping synthetic 9-met peptides (in- 
cluding the p939 sequence) derived from the MART-1 gene 
for CTL reactivity. In particular,  they failed to demonstrate 
CTL recognition of the p939;ILTVILGVL sequence) presented 
by the T2 cell line using two of the same cellular reagents 
(TIL 1235 and done A42) used in this study. This discrepancy 
appears  to be due to the peptide-loading conditions used in 
their study. Unlike Kawakami et al.  (17), we allow epitope 
reconstitution to occur in the presence of exogenous human 
32-m  and  MA2.1  (anti-HLA-A2  monoclonal  antibody). 
This facilitates  peptide loading into HLA-A2 complexes by 
100-1,000-fold (8, 22-24). Without these additions, we have 
similarly observed only marginal CTL reactivity (5-10% over 
background) against p939-1oaded T2 target cells. This require- 
ment for 132-m and MA2.1  appears  to reflect the apparent 
low affinity ofp939 for HLA-A2 in the assay system we used 
for assessing CTL reactivity and may represent an important 
consideration in the development of p939-based vaccine strate- 
gies.  Despite  this  low  affinity,  enough  p939  peptide  was 
presented in HLA-A2 complexes on the cell surface of Mel 
9742  cells  to  allow  for  CTL  reactivity  as  well  as  p939 
identification  and  sequencing.  This  suggests  that  p939  is 
efficiently processed and loaded into HLA-A2 molecules via 
the endogenous pathway in melanoma cells. 
Since anti-p939 reactivity could be demonstrated for five 
distinct CTL populations derived from unrelated HLA-A2 + 
melanoma patients, p939 may serve as an important compo- 
nent in an effective peptide-based vaccine for the treatment 
of melanoma. Given the apparent  subtleties in the p939-HLA- 
A2 loading requirements,  such therapies may best take the 
form of ex vivo pulsed autologous antigen presenting cells 
(i.e.,  dendritic cells) used as a vaccine (29) or moderate-to- 
high dose intradermal immunization of p939. Alternatively, 
p939 may be used to expand antimelanoma CTL in vitro for 
subsequent  adoptive immunotherapy. 
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